Project Grant R43HD107685

Award Date 9/21/21
Completion Date 2/28/23
Dollars Obligated $897K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92122, USA
Similar Awards
Hera Health Solutions Inc. received a $275,000 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program to develop a biodegradable contraceptive-releasing implant. The award aims to advance long-acting reversible contraception by creating an implant that delivers consistent hormone doses and does not require surgical removal. During the one-year period from May 1, 2023 to April 30, 2024, the company will characterize the drug delivery scaffold,...
The National Institute of Child Health and Human Development (NICHD) awarded Contraline, Inc. a $291,440 Project Grant (CFDA 93.865) to develop ADAM AIR, a non-hormonal, vas-occlusive contraceptive device for men. ADAM AIR is an aerogel formulation that can be implanted into the vas deferens to block sperm flow, providing long-lasting contraceptive effects that are reversible on-demand. This award supports research to reduce manufacturing and procedural complexities compared to the initial...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to develop a bioadhesive vaginal film that can provide extended release of contraceptive and antiviral monoclonal antibodies. The $518,754 award, with a performance period from February 1, 2025 to January 31, 2026, will fund research by the Magee-Womens Research Institute and Foundation, with sub-awards to...
This $380,692 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports the development of an ultrapotent anti-sperm antibody construct for a non-hormonal contraceptive intravaginal ring. The recipient, Mucommune LLC, a Durham, North Carolina-based biopharmaceutical company, aims to formulate and characterize the release kinetics and activity of the LAMH10...
This Project Grant award from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $1,514,498 to Madorra Inc., a for-profit small business, to develop and test an at-home, non-hormonal medical device to treat vulvovaginal atrophy (VVA) in peri- and post-menopausal women, including breast cancer survivors. The Madorra Therapy System uses therapeutic ultrasound to increase vaginal blood flow and...
This $300,000 Cooperative Agreement awarded by the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) under the FDA Research Program (CFDA 93.103) aims to develop physiologically-based pharmacokinetic (PBPK) models and mechanistic in vitro-in vivo correlations (IVIVC) for long-acting injectable (LAI) drug suspensions. The research will comprehensively investigate the relationships between the physicochemical properties of LAI formulations, such as...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $384,923 to Lumina Medical LLC for the development of an innovative and affordable vaginal dilation device. The device aims to significantly improve pain management for patients with chronic pelvic floor disorders, including post-menopausal vaginal atrophy, vaginal stenosis, and others affecting over 25 million women...
This Project Grant award of $681,884 from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support a longitudinal study on the life course impacts of reduced access to contraception in Texas. The key objectives are to: Expand an individual-level longitudinal dataset, Reproduction in People's Lives (RIPL), which links comprehensive Census and IRS data to track women's fertility and human...
The National Institute of Child Health and Human Development (NICHD) awarded a $343,510 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to Theranova LLC, a veteran-owned medical device company based in San Francisco, CA. The grant supports the development and pilot evaluation of the SOLESTIM neuromodulation system, a portable, non-invasive device designed to treat dysmenorrhea (menstrual cramps) through plantar nerve stimulation. The...
This $704,672 Phase I SBIR Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of an implantable medical device to improve vascular access and safety for hemodialysis patients. The project aims to refine the manufacturability and operational parameters of a 3D-printed titanium device that accurately guides the hemodialysis needle and...

SUBCUTANEOUS INSERTION AND REMOVAL OF A USER-CONTROLLED, LONG-ACTING, AND REVERSIBLE CONTRACEPTIVE DEVICE - MODERN CONTRACEPTIVES NOT ONLY PLAY A CRITICAL ROLE IN PREVENTING UNPLANNED PREGNANCY BUT ALSO CONTRIBUTE TO A WOMAN'S WELL-BEING BY EMPOWERING HER WITH THE NECESSARY RESOURCES TO CONTROL HER OWN REPRODUCTIVE HEALTH, INCLUDING THE NUMBER OF, AND SPACING BETWEEN, CHILDREN. DESPITE THE GROWING RECOGNITION THAT NO ONE CONTRACEPTIVE METHOD WORKS WELL FOR ALL WOMEN ALL OF THE TIME, ADVANCES IN THE CONTRACEPTIVE MARKET OVER THE PAST SEVERAL DECADES HAVE BEEN INCREMENTAL. A HIGH-IMPACT DRIVER OF THE GROWING CONTRACEPTIVES MARKET IS THE NUMBER OF UNINTENDED PREGNANCIES, THE RISK OF WHICH IS INCREASED WHEN CONTRACEPTIVES ARE USED INCORRECTLY, INCONSISTENTLY, OR NOT AT ALL. THE UNINTENDED PREGNANCY RATE IN THE U.S. IS SIGNIFICANTLY HIGHER THAN IN MANY OTHER DEVELOPED COUNTRIES, WITH NEARLY 5% OF REPRODUCTIVE-AGE WOMEN HAVING AN UNINTENDED PREGNANCY EACH YEAR. UNINTENDED PREGNANCY IS ASSOCIATED WITH ANNUAL DIRECT MEDICAL COSTS IN THE BILLIONS OF DOLLARS IN THE U.S., AS WELL AS SIGNIFICANT MEDICAL RISK, PARTICULARLY FOR WOMEN AT BOTH ENDS OF THE REPRODUCTIVE AGE SPAN WHO ARE LESS LIKELY TO SEEK ADEQUATE PRECONCEPTION CARE. TO MEET THE NEED FOR NEW CONTRACEPTIVE OPTIONS FOR WOMEN, DARE BIOSCIENCE IS ADVANCING THE DEVELOPMENT OF DARE-LARC1. DARE-LARC1 IS AN IMPLANTABLE DEVICE THAT DELIVERS THE COMMON CONTRACEPTIVE LEVONORGESTREL OVER AT LEAST TEN YEARS. UNLIKE EXISTING LONG-ACTING, REVERSIBLE CONTRACEPTIVES, DELIVERY CAN BE TURNED ON AND OFF WIRELESSLY, THEREBY PROVIDING WOMEN AND COUPLES WITH A SAFE, CONVENIENT, AND EFFECTIVE CONTRACEPTIVE OPTION TO TIME AND SPACE PREGNANCIES. THE OBJECTIVE OF THIS SBIR PHASE I PROPOSAL IS TO DEMONSTRATE THE FEASIBILITY OF DEVICE INSERTION AND REMOVAL. THE WORK UNDERTAKEN DURING THE FUNDING PERIOD WILL RESULT IN (1) IDENTIFICATION OF THE FEASIBLE SITE(S) OF DARE-LARC1 INSERTION IN THE UPPER ARM AND (2) DEFINITION OF PRELIMINARY INSERTION CRITERIA. THE SUCCESSFUL ACCOMPLISHMENT OF ALL MILESTONES IN THIS PROPOSAL WILL ADVANCE DARE-LARC1 RESEARCH AND DEVELOPMENT TO FUTURE STUDIES FOCUSED ON THE DEVELOPMENT OF CUSTOM TOOLS FOR DARE-LARC1 INSERTION AND REMOVAL.

Posted 9/21/21, 12:00 AM